AMYRA Biotech
AMYRA Biotech AG is a company focused on developing innovative digestive enzyme supplements and therapeutics through AI-powered protein characterization and computational enzymology. Their core technology, Brush Border Enzyme Supplementation Technology (BBEST), aims to supplement the activity of natural digestive enzymes in the small intestine. The lead product, AMYNOPEP01, is a synergistic combination of exopeptidases designed to enhance the digestion of hard-to-digest foods, particularly protein fragments like gluten, and improve nutrient bioavailability. AMYRA's pipeline spans both consumer health products and pharmaceutical applications for conditions including food sensitivities and gastrointestinal diseases. The company leverages a decade of experience in enzyme development and manufacturing, with a mission to address compromised digestive function caused by factors like chronic inflammation.
AMYRA Biotech
AMYRA Biotech AG is a company focused on developing innovative digestive enzyme supplements and therapeutics through AI-powered protein characterization and computational enzymology. Their core technology, Brush Border Enzyme Supplementation Technology (BBEST), aims to supplement the activity of natural digestive enzymes in the small intestine. The lead product, AMYNOPEP01, is a synergistic combination of exopeptidases designed to enhance the digestion of hard-to-digest foods, particularly protein fragments like gluten, and improve nutrient bioavailability. AMYRA's pipeline spans both consumer health products and pharmaceutical applications for conditions including food sensitivities and gastrointestinal diseases. The company leverages a decade of experience in enzyme development and manufacturing, with a mission to address compromised digestive function caused by factors like chronic inflammation.